Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

HIV vaccines.

Andrew J McMichael1

  • 1MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS UK. andrew.mcmichael@ndm.ox.ac.uk

Annual Review of Immunology
|March 23, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HLA-E-restricted T cells primed by a modified HLA-B*57:01 restricted HIV-1 peptide suppress HIV-1 replication.

JCI insight·2026
Same author

Nonclassical MHC-I Molecules: Emerging Therapeutic Targets in Next-Generation Immunotherapy.

MedComm·2026
Same author

Shared HLA-E and Mamu-E Peptide Repertoires With Subtle Peptide Binding Differences Revealed by Combined nDSF- and Fluorescence Polarisation-Based Methods.

European journal of immunology·2026
Same author

A cytoplasmic motif in HLA-E that drives clathrin-mediated endocytosis and VCP-associated postendocytic trafficking.

Proceedings of the National Academy of Sciences of the United States of America·2025
Same author

Targeting MHC-E as a new strategy for vaccines and immunotherapeutics.

Nature reviews. Immunology·2025
Same author

HLA-E: Immune Receptor Functional Mechanisms Revealed by Structural Studies.

Immunological reviews·2025
Same journal

The Neuroimmune Circuitry of Peripheral Sensory Neuron Subtypes in Chronic Pain.

Annual review of immunology·2026
Same journal

The Spectrum of Fibroblast Immune Biology.

Annual review of immunology·2026
Same journal

The Molecular Logic of Immunoglobulin Heavy Chain Class Switch Recombination.

Annual review of immunology·2026
Same journal

Decoding Human T Cell Immunity with Artificial Intelligence and Single-Cell Genomics.

Annual review of immunology·2026
Same journal

Immune Niches in Cancer.

Annual review of immunology·2026
Same journal

T Cell Receptor Signaling and Immune Tolerance: From Autoimmunity to Cancer Immunity.

Annual review of immunology·2026
See all related articles

Developing an effective human immunodeficiency virus type 1 (HIV-1) vaccine remains challenging due to viral evasion. Current strategies aim to elicit neutralizing antibodies or T cell responses, with SIV macaque models offering insights.

Area of Science:

  • Virology
  • Immunology
  • Vaccinology

Background:

  • A prophylactic vaccine for human immunodeficiency virus type 1 (HIV-1) is urgently needed but remains elusive after two decades of research.
  • HIV-1 has evolved sophisticated mechanisms to evade neutralizing antibodies via its envelope.
  • The virus also evades T cell responses through continuous mutation.

Purpose of the Study:

  • To review the challenges and progress in developing an HIV-1 vaccine.
  • To discuss the potential of stimulating neutralizing antibodies and T cell immunity.
  • To consider the implications of SIV macaque models and therapeutic vaccination.

Main Methods:

  • Review of existing research on HIV-1 vaccine development.
  • Analysis of viral evasion strategies (antibody and T cell).

Related Experiment Videos

  • Evaluation of animal models (SIV in macaques) and therapeutic vaccination concepts.

    • Main Results:

    • Significant progress in understanding HIV-1's evasion tactics has been made.
    • Stimulating broadly reactive and persistent T cell responses may suppress, but not prevent, infection.
    • SIV macaque models provide some encouragement but require further investigation.

    Conclusions:

    • Despite challenges, a vaccine inducing neutralizing antibodies is still the primary goal.
    • T cell-focused vaccine strategies may offer partial control of HIV-1 infection and disease.
    • Further research into SIV models and therapeutic vaccination is warranted.